Neoadjuvant therapy of rectal carcinoma with UFT–leucovorin plus radiotherapy

Abstract

BackgroundThe object of this phase II study was to assess the impact of preoperative external radiation therapy combined with UFT and leucovorin on tumor response, sphincter preservation and tumor control in patients with rectal carcinoma. Patients and methodsForty-one patients with resectable extraperitoneal rectal adenocarcinoma received radiation therapy and two courses of chemotherapy. Chemotherapy consisted of a 2-h infusion of 6S-steroisomer of leucovorin (6SLV) 250 mg/m2 on day 1, oral 6SLV 7.5 mg every 12 h on days 2–14, and UFT either 350 or 300 mg/m2 on days 1 to 14 every 28 days. Six additional courses of chemotherapy were given after surgery. ResultsSeven of 16 patients (43%) who received 350 mg/m2/day of UFT had grade 3–4 diarrhea and two other patients (12%) had grade 3–4 dermatitis. The next 25 patients received 300 mg/m2/day of UFT and only 14% of them had grade 3–4 diarrhea. Surgery consisted of low-anterior resection in 26 patients (63%) and abdominal-perineal amputation in 15 (37%). There were six histological complete responses (15%). Downstaging occurred in 25 patients (63%). The overall survival at 3 years was 90% and the pelvic disease-free survival 92%. ConclusionsPreoperative therapy with radiotherapy and UFT–6SLV downstaged 63% of tumors and allowed a sphincter-preserving procedure in some patients. Toxicity was moderate. This scheme is convenient because of the oral administration of chemotherapy.